Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 10 results
Author Title Type [ Year(Asc)]
Filters: Author is Feagan, Brian G  [Clear All Filters]
2021
Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al..  2021.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al..  2021.  Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.
2020
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al..  2020.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.
2019
Battat R, Ma C, Jairath V, Khanna R, Feagan BG.  2019.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.. Drug Saf. 42(5):617-632.
Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Casteele NVande et al..  2019.  Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Am J Gastroenterol. 114(5):733-745.
Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V.  2019.  Innovations in Oral Therapies for Inflammatory Bowel Disease.. Drugs. 79(12):1321-1335.
2018
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
2008
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.